2 GLP-1 Stocks That Could Double Your Money by 2031
They are fairly risky, but their potential upside is massive.
Overview
The GLP-1 market may be one of the fastest-growing in the pharmaceutical industry right now. Many of the largest drugmakers are looking to capitalize on this and are developing promising GLP-1 candidates. The list includes Roche (OTC: RHHBY), Regeneron Pharmaceuticals (NASDAQ: REGN), Amgen (NASDAQ: AMGN), and others. However, there are also smaller biotechs looking to tap into this market, such as Viking Therapeutics (NASDAQ: VKTX) and Kailera Therapeutics (NASDAQ: KLRA).
Investing in these less prominent players carries substantially more risk. They aren't as well-established as their larger peers and could lose significant market value overnight due to clinical setbacks. However, Viking Therapeutics and Kailera Therapeutics also arguably have more upside potential. Here's why these stocks could double investors' money by 2031.
Image source: The Motley Fool.
Details
Source
Originally published at www.fool.com.